Magenta Therapeutics (MGTA) Sees Coverage Initiated By JPMorgan with a $18.0 Price

July 16, 2018 - By Kristin Houston

Why Has JPMorgan Given Magenta Therapeutics (MGTA) a $18.0 Price Target

Stock analysts at JPMorgan placed a key “Overweight” rating for Magenta Therapeutics (MGTA). The firm began coverage in analysts report published on Monday, 16 July. The PT means upside of 42.86 % from the close price.

The stock decreased 5.69% or $0.76 during the last trading session, reaching $12.6. About 129,629 shares traded. Magenta Therapeutics, Inc. (MGTA) has 0.00% since July 16, 2017 and is . It has underperformed by 12.57% the S&P500.

Magenta Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing medicines to bring the curative power of bone marrow transplant to patients. The company has market cap of $410.03 million. It is developing C100, C200, and C300 targeted antibody-drug conjugates for transplant conditioning; MGTA-145, a stem cell mobilization product candidate to control stem cell mobilization; MGTA-456, an allogeneic stem cell therapy to control stem cell growth; E478, a small molecule aryl hydrocarbon receptor antagonist for the expansion of gene-modified stem cells; and G100, an ADC program to prevent acute graft and host diseases. It currently has negative earnings. The firm was formerly known as HSCTCo Therapeutics, Inc. and changed its name to Magenta Therapeutics, Inc. in February 2016.

More notable recent Magenta Therapeutics, Inc. (NASDAQ:MGTA) news were published by: Benzinga.com which released: “Benzinga’s Daily Biotech Pulse: Epidiolex, Roche’s Influenza Drug Gets Priority Review Status, Xeris Jumps On …” on June 26, 2018, also Nasdaq.com with their article: “Retailers, Markets React To Supreme Court Ruling On Online Sales Taxes” published on June 21, 2018, Streetinsider.com published: “Magenta Therapeutics (MGTA) IPO Opens Modestly Higher” on June 21, 2018. More interesting news about Magenta Therapeutics, Inc. (NASDAQ:MGTA) were released by: Nasdaq.com and their article: “Nasdaq’s Hot First Day of Summer – Six IPOs Join our Market” published on June 22, 2018 as well as Benzinga.com‘s news article titled: “The Week Ahead In Biotech: Conferences, Clinical Trial Results, IPOs And More” with publication date: July 14, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.